RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
RemeGen, a Yantai biologics company, reported its HER2-targeting antibody-drug conjugate produced a 51% objective response rate in a China Phase II trial of patients with HER2-positive urothelial cancer. The candidate, RC48, was developed to treat HER2-positive solid tumors. It includes a novel HER2-monoclonal antibody, a cathepsin cleavable linker and a cytotoxic payload. Compared to the current standard of care, the monoclonal antibody has a higher affinity for HER2 and, in animal models, showed higher anti-tumor activity. RemeGen said RC48 is the first ADC drug approved in China for human clinical trials.
Source: China Biotoday
